These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33284613)

  • 1. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
    Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
    J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
    Shirasaki R; Matthews GM; Gandolfi S; de Matos Simoes R; Buckley DL; Raja Vora J; Sievers QL; Brüggenthies JB; Dashevsky O; Poarch H; Tang H; Bariteau MA; Sheffer M; Hu Y; Downey-Kopyscinski SL; Hengeveld PJ; Glassner BJ; Dhimolea E; Ott CJ; Zhang T; Kwiatkowski NP; Laubach JP; Schlossman RL; Richardson PG; Culhane AC; Groen RWJ; Fischer ES; Vazquez F; Tsherniak A; Hahn WC; Levy J; Auclair D; Licht JD; Keats JJ; Boise LH; Ebert BL; Bradner JE; Gray NS; Mitsiades CS
    Cell Rep; 2021 Jan; 34(1):108532. PubMed ID: 33406420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
    Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
    Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.
    Yu X; Xu J; Xie L; Wang L; Shen Y; Cahuzac KM; Chen X; Liu J; Parsons RE; Jin J
    J Med Chem; 2021 Dec; 64(24):18054-18081. PubMed ID: 34855399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
    Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
    J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
    Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
    Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
    Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
    ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
    Wang H; Li C; Liu X; Ma M
    Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
    Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
    J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia.
    Wang X; Zhang X; Li BS; Zhai X; Yang Z; Ding LX; Wang H; Liang C; Zhu W; Ding J; Meng LH
    Oncotarget; 2014 Nov; 5(21):10732-44. PubMed ID: 25313141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
    Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
    Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
    Zhao Q; Ren C; Liu L; Chen J; Shao Y; Sun N; Sun R; Kong Y; Ding X; Zhang X; Xu Y; Yang B; Yin Q; Yang X; Jiang B
    J Med Chem; 2019 Oct; 62(20):9281-9298. PubMed ID: 31539241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader.
    Wei J; Hu J; Wang L; Xie L; Jin MS; Chen X; Liu J; Jin J
    J Med Chem; 2019 Dec; 62(23):10897-10911. PubMed ID: 31730343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.